SEARCH

SEARCH BY CITATION

References

  • 1
    DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794811.
  • 2
    Cherry SB, Benner JS, Hussein MA, et al.The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health.2009;12:489497.
  • 3
    Vrijens B, Vincze G, Kristanto P, et al.Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:11141117.
  • 4
    Chobanian AV, Bakris GL, Black HR, et al.Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 5
    Mancia G, De Backer G, Dominiczak A, et al.2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 6
    Riess W, Dubach UC, Burckhardt D, et al.Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol. 1977;12:375382.
  • 7
    Ribeiro AB, Mion D Jr, et al; for the Latin American Hypertension Study (LAMHYST) Group. Antihypertensive efficacy of amlodipine and losartan after two ‘missed’ doses in patients with mild to moderate essential hypertension. J Int Med Res. 2007;35:762772.
  • 8
    Vaidyanathan S, Limoges D, Yeh C, Dieterich H. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers. Clini Pharmacol Ther.2006;79:64.
  • 9
    Vaidvanathan S, Zhao C, Yeh C, Dieterich H. Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes. Clin Pharmacol Ther. 2006;79:12.
  • 10
    McInnes G. 24-hour powerful blood pressure-lowering: is there a clinical need?J Am Soc Hypertens.2008;4(suppl):S16S22.
  • 11
    Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract. 2011;65:127133.
  • 12
    Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 1996;17(suppl A):815.
  • 13
    Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev. 1998;33:207219.
  • 14
    Wood JM, Maibaum J, Rahuel J, et al.Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698705.
  • 15
    Galzerano D, Capogrosso C, Di Michele S, et al.New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag.2010;6:113133.
  • 16
    Düsing R, Brunel P, Baek IY, Baschiera F. Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double blind, randomized, study. J Hypertens. 2011;30:10291040.
  • 17
    Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens. 1999;6:973985.
  • 18
    Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19:11901196.
  • 19
    Shaya FT, Du D, Gbarayor CM, et al.Predictors of compliance with antihypertensive therapy in a high-risk Medicaid population. J Natl Med Assoc. 2009;101:3439.
  • 20
    Mazzaglia G, Ambrosioni E, Alacqua M, et al.Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:15981605.
  • 21
    Hyre AD, Krousel-Wood MA, Muntner P, et al.Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich).2007;9:179186.
  • 22
    Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail.2003;9:324332.
  • 23
    Lowy A, Munk VC, Ong SH, et al.Effects on blood pressure and cardiovascular risk of variations in patients’ adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract. 2011;65:4153.
  • 24
    Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther. 1994;1:260267.
  • 25
    Hernandez-Hernandez R, Armas de Hernandez MJ, Armas-Padilla MC, et al.The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Press Monit.1996;1:121126.
  • 26
    Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens. 1999;12(Pt 1–2)11811187.
  • 27
    Hermida RC, Ayala DE, Khder Y, Calvo C. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther. 2008;30:108120.
  • 28
    Zhu JR, Bai J, Cai NS, et al.Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl.2004;145:4649.
  • 29
    White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens. 2004;17:347353.
  • 30
    Lacourciere Y, Lenis J, Orchard R, et al.A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit.1998;3:295302.
  • 31
    Gosse P, Neutel JM, Schumacher H, et al.The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit.2007;12:141147.
  • 32
    Palatini P, Jung W, Shlyakhto E, et al.Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens. 2010;24:93103.
  • 33
    Oh BH, Mitchell J, Herron JR, et al.Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:11571163.
  • 34
    Andersen K, Weinberger MH, Egan B, et al.Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26:589599.
  • 35
    Herron J, Mitchell J, Oh B. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J Clin Hypertens.2006;5(suppl A):A86A87.
  • 36
    Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1E8.
  • 37
    Williams B, Baschiera F, Lacy PS, et al.Blood pressure and plasma renin activty responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise. J Renin Angiotensin Aldosterone Syst. 2012 Aug 2. [Epub ahead of print]
  • 38
    Gosse P, Coulon P, Brossaud J, Corcuff JB. A simple test to appreciate compliance to aliskiren treatment. J Hypertens. 2011;29:2038.
  • 39
    Wenzel U, Stange D, Düsing R. A simple test to appreciate compliance with antihypertensive drug therapy. J Hypertens. 2012;30:624.
  • 40
    Lowy A, Brede Y. Duration of action of aliskiren in hypertensive patients with diabetes. Implications for control of blood pressure in realworld use in imperfectly adherent patients. Value Health.2011;14:A368.
  • 41
    Boschmann M, Nussberger J, Engeli S, et al.Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens. 2012;30:561566.
  • 42
    Feldman DL, Persohn E, Schutz H, et al.Renal localization of the renin inhibitor aliskiren (abstract). J Clin Hypertens.2006;8(suppl A):A80.
  • 43
    Düsing R, Brunel P, Baek IY, Baschiera F. Sustained blood pressure lowering effect of aliskiren compared to telmisartan 48 hours after treatment withdrawal. Hypertension. 2011;58:e33e183.
  • 44
    Hernandez RH, Armas-Hernandez MJ, Chourio JA, et al.Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Press Monit.2001;6:4757.
  • 45
    Ongtengco I, Morales D, Sanderson J, et al.Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two ‘missed doses’: a randomised, double-blind comparative trial in Asian patients. J Hum Hypertens. 2002;16:805813.
  • 46
    Vaur L, Dutrey-Dupagne C, Boussac J, et al.Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol. 1995;26:127131.
  • 47
    Tomlinson B, Woo J, Thomas GN, et al.Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult Chinese patients with hypertension. Clin Ther. 2004;26:12921304.